Navigation Links
Bone drug zoledronic acid may help prevent spread of early lung cancer
Date:2/25/2011

A drug that is currently used to help treat bone metastases in patients with lung cancer could also be useful at an earlier stage of treatment, to prevent the cancer from spreading in the first place, Italian researchers have found.

Dr Michela Quirino and colleagues from the Catholic University of the Sacred Heart in Rome have reported important new evidence that zoledronic acid may be able to prevent lung cancer metastases from recruiting the new blood vessels they need to survive. This process of recruiting new blood vessels is called angiogenesis.

"Our investigation represents the first clear clinical evidence of the anti-angiogenic effect of zoledronic acid in patients with metastatic lung cancer," Dr Quirino said. "It also represents the first biological basis in lung cancer for the clinical investigation of zoledronic acid not only for metastatic lung cancer, but also in early disease."

Dr Quirino presented findings from a study of 41 patients with advanced lung cancer.

Each patient was administered 4 mg of zoledronic acid, and their blood levels of several molecular markers of angiogenesis were measured before and 48 hours after the injection. Those markers included the molecules VEGF, PDGF, b-FGF and HGF.

"We found a statistically significant reduction of VEGF levels at day 2 after 4 mg ZA intravenous infusion compared with basal values," Dr Quirino said. Blood levels of bFGF were also significantly reduced. "Some studies reported that VEGF secretion is induced by bFGF and this could support our results," she added.

The researchers did not record any significant effect of injecting the drug on the levels of the other two mediators of angiogenesis, PDGF and HGF.

Treatment with zoledronic acid is already an important treatment to manage bone metastases from lung cancer, Dr Quirino noted. Some clinical studies have already demonstrated that zoledronic acid in bone metastases from lung cancer improves clinical outcomes and patient survival.

"If further studies should confirm a possible anti-metastatic effect of this drug, possibly relying also on its anti-angiogenic effect, it could be introduced in the early management of the disease, even as an adjuvant therapy."

Commenting on the study, which he was not involved in, Prof Ken O'Byrne, from St James's Hospital in Dublin, Ireland, said: "These observations underline the importance of targeting VEGF in non-small cell lung cancer and the potential role bFGF may have in tumor growth and metastasis. The results lay the groundwork for evaluating the potential role of zoledronic acid in the treatment of lung cancer independently of the effects on bone metastases."


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. Vaccine May Prevent TB in People With HIV
2. Prevention Is Key Research Goal for Premature Babies, Scientists Say
3. Hormone May Prevent Aggressive Breast Cancer
4. Pet Dental Month Prime Time To Schedule Preventive Annual Cleaning For Pets
5. Botox May Prevent Some Migraines
6. Medical Nurse Training, Inc. Partners With Healthcare Companies to Develop Corporate Branded, Accredited Programs for Patient/Bed Safety and Fall Prevention/Protection
7. VIDEO from Medialink and AAFA: Asthma PSA Reinforces Prevention of Asthma Symptoms
8. Northern California Cancer Center Changes Name to Cancer Prevention Institute of California
9. New Safety Bath and Sill Mats Help Prevent Slip and Fall in Bathrooms - from Martinson-Nicholls
10. Sacred Heart Medical Center Cited for Violation of Safety Standards in H1N1 Prevention
11. African-Americans attitudes about lung cancer may hinder prevention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology: